TMCnet News
Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life UnitsCHICAGO, June 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a distribution agreement with International Medical Company ("IMC") to expand its presence in the State of Qatar for its proprietary Sky Premium Life® line of nutraceuticals and food supplements. In connection with the agreement, IMC has placed an initial purchase order of 31,000 units. Founded in 1998, IMC is Qatar's fastest-growing pharmaceutical retailer and distributor and one of the sector's leading employers, with a team of over 1,400 operating across its Sales & Marketing, Pharmacy, and Consumer divisions. Its retail arm, Kulud Pharmacies, is the largest pharmacy chain in the country, with over 130 branches and a portfolio of more than 12,000 products. The partnership gives Sky Premium Life broad consumer reach from the outset, supported by an established nationwide retail network.
The agreement marks a further step in Cosmos Health's international expansion of Sky Premium Life across high-growth Gulf markets. Under its terms, IMC will manage all key functions in the territory, including sales and marketing, regulatory affairs, logistics, supply, and distribution. Greg Siokas, CEO of Cosmos Health, stated: "Qatar is one of the Gulf's most dynamic healthcare markets, and partnering with IMC and its Kulud Pharmacies network puts Sky Premium Life directly in front of consumers at scale from day one. This is exactly the kind of high-impact partnership we are pursuing as we accelerate Sky Premium Life's global growth.” About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broadline of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements Investor Relations Contact: A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ef90832-64c8-4caa-9750-36188d238105
|



